BioStock: Synact focuses on pushing forward rheumatoid arthritis project

SynAct Pharma is intent on making a turnaround after posting disappointing study results with lead asset resomelagon. The Swedish biotech is conducting a directed share issue of SEK 49.2 million to develop resomelagon further in rheumatoid arthritis. BioStock got in touch with Synact’s CSO Thomas Jonassen to learn more.

Read the article at biostock.se:

https://www.biostock.se/en/2024/04/synact-focuses-on-pushing-forward-rheumatoid-arthritis-project/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/